Stocks · News reference
Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.68) by 7.35 percent. This is a 35.05 percent increase over losses of $(0.97) per share
Read original at benzinga192.22 +4.44 [+2.36%]
Read original at benzingaFiled: 2026-07-27 AccNo: 0001193125-26-316916 Size: 227 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgar